ISC-4 also has exhibited significant anti-tumor effects, via the inhibition of Akt, in colon cancer xenografts when used as a mono-agent and when used in combination with 5-fluorouracil (5-FU)—though the clinical utility of the combination was unclear [5]. The gene discussed is AKT1; the disease is neoplasm.